<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:creator>Neri D</dc:creator>
  <dc:creator>Sondel PM</dc:creator>
  <dc:date>2016</dc:date>
  <dc:description xmlns:ns0="xml" ns0:lang="en">Immunocytokines are antibody-cytokine fusion proteins, with the potential to preferentially localize on tumor lesions and to activate anticancer immunity at the site of disease. Various tumor targets (e.g., cell membrane antigens and extracellular matrix components) and antibody formats (e.g., intact IgG and antibody fragments) have been considered for immunocytokine development and some products have advanced to clinical trials. In this review, we present relevant concepts and strategies for the design and use of anticancer immunocytokine products. In addition, we discuss emerging strategies for the pharmaceutical development and clinical application of this promising class of biopharmaceuticals.</dc:description>
  <dc:format>application/pdf</dc:format>
  <dc:identifier>https://sonar.ch/global/documents/127044</dc:identifier>
  <dc:language>eng</dc:language>
  <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1016/j.coi.2016.03.006</dc:relation>
  <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/27060634</dc:relation>
  <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
  <dc:source>Current opinion in immunology. - 2016</dc:source>
  <dc:subject xmlns:ns1="xml" ns1:lang="en">Animals</dc:subject>
  <dc:subject xmlns:ns2="xml" ns2:lang="en">Antibodies, Monoclonal</dc:subject>
  <dc:subject xmlns:ns3="xml" ns3:lang="en">Cell Movement</dc:subject>
  <dc:subject xmlns:ns4="xml" ns4:lang="en">Clinical Trials as Topic</dc:subject>
  <dc:subject xmlns:ns5="xml" ns5:lang="en">Cytokines</dc:subject>
  <dc:subject xmlns:ns6="xml" ns6:lang="en">Humans</dc:subject>
  <dc:subject xmlns:ns7="xml" ns7:lang="en">Immunotherapy</dc:subject>
  <dc:subject xmlns:ns8="xml" ns8:lang="en">Killer Cells, Natural</dc:subject>
  <dc:subject xmlns:ns9="xml" ns9:lang="en">Lymphocyte Activation</dc:subject>
  <dc:subject xmlns:ns10="xml" ns10:lang="en">Neoplasms</dc:subject>
  <dc:subject xmlns:ns11="xml" ns11:lang="en">Recombinant Fusion Proteins</dc:subject>
  <dc:subject xmlns:ns12="xml" ns12:lang="en">T-Lymphocytes</dc:subject>
  <dc:title xmlns:ns13="xml" ns13:lang="en">Immunocytokines for cancer treatment: past, present and future.</dc:title>
  <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
</oai_dc:dc>